Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) FCF Margin: 2016-2024

Historic FCF Margin for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to 540,966.67%.

  • Summit Therapeutics' FCF Margin was N/A to 540,966.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 1,637.64%, marking a year-over-year change of. This contributed to the annual value of 1,637.64% for FY2024, which is 114030.00% up from last year.
  • Summit Therapeutics' FCF Margin amounted to 540,966.67% in Q4 2024, which was up 43,633.56% from 1,236.96% recorded in Q3 2024.
  • Over the past 5 years, Summit Therapeutics' FCF Margin peaked at 540,966.67% during Q4 2024, and registered a low of -3,879.55% during Q3 2022.
  • Over the past 2 years, Summit Therapeutics' median FCF Margin value was 1,065.93% (recorded in 2024), while the average stood at 108,071.13%.
  • Data for Summit Therapeutics' FCF Margin shows a maximum YoY tumbled of 369,860bps (in 2020) over the last 5 years.
  • Over the past 3 years, Summit Therapeutics' FCF Margin (Quarterly) stood at -1,538.33% in 2020, then followed by -3,879.55% in 2022, then followed by 540,966.67% in 2024.
  • Its last three reported values are 540,966.67% in Q4 2024, 1,236.96% for Q3 2024, and 1,065.93% during Q2 2024.